M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
ASCO 2025 – BioNTech shows promise in mesothelioma
BNT327 could rival Keytruda and Opdivo, but toxicity is worth watching.
ASCO 2025 – BioNTech’s latest Claudin6 effort falls short
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
Pfizer bets big on a bispecific
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Qilu nabs a new B7-H3 contender
Minghui’s MHB088C will soon start phase 3 in China.
AACR 2025 – BioNTech sees its first combo glimmers
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
